Clinical Trials

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled 19 charts

Phase 1 Enrolling by invitation

Lymphoma, AIDS-Related

NCT06788509 2026-04-13

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT02537613 2026-04-01

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

54 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02446236 2026-03-24

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

27 enrolled 11 charts

Lymphoma, Mantle-Cell

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07082868 2026-02-17

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Phase 1 Recruiting

26 enrolled

CNSLymphoid

Primary Central Nervous System Lymphoma (PCNSL)

NCT03021460 2026-01-20

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

20 enrolled

Dermatologic

Melanoma

NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Phase 1 Recruiting

37 enrolled

CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT02787369 2026-01-07

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

3 enrolled

Leukemia, Leukemia, B-Cell

NCT03447808 2026-01-07

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

15 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

14 enrolled 15 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03479268 2025-11-26

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

18 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT01955499 2025-11-10

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

39 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03535350 2025-09-30

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1 Not yet recruiting

36 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

21 enrolled

Waldenstrom Macroglobulinemia

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

50 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04876092 2025-08-21

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

45 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03015792 2025-08-17

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Phase 1 Terminated

18 enrolled

Plasma cell

Multiple Myeloma

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

34 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03400176 2025-05-16

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Phase 1 Terminated

39 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03939182 2025-04-25

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

15 enrolled